A busy weekend here in #Barcelona with a brainstorming ETOP IBCSG Partners Foundation meeting full of innovative concepts and new collaborations, followed by the Global Lung Cancer Summit recapitulating all important advances in 2024 by international experts!! Thrilled to meet friends around the

With the North Estonia Medical Centre, the first European site has been activated for our ETOP 25-23 ADOPT-lung trial: etop.ibcsg.org/projects/clini…; Thoracic Oncology Group of Australasia, NHMRC CTC, SAKK

The phase III ETOP 25-23 ADOPT-lung will try to determine the benefit of adjuvant immunotherapy after neoadjuvant chemo-IO, outlined in Lung Cancer Journal. Pts with resectable stage IIA-IIIB NSCLC receive induction durvalumab + chemo, then randomized to 1y of durva vs observation.

Triparna Sen (Sen-Lab) gives a masterclass presentation on SCLC subtypes, their biological significance & implication for possible treatments ETOP IBCSG Partners Foundation

Day #2 ETOP IBCSG Partners Foundation workshop Lessons from haematology about T-cell engagers 🔺 Several potential toxicities 🔺 Haemophagocytic syndrome ❗️ ✅ Combination with chemo possible ✅ Use CRS prophylaxis

Back in Zurich for another exceptional ETOP IBCSG Partners Foundation workshop, now focusing on T-cell engagers (TCE) and their unprecedented benefit in #SCLC. An amazing group of colleagues who paved preclinical/clinical development discussed the presence and the future of TCEs. Watch this

Sumanta K. Pal, MD, FASCO Matthew Lee Balazs Halmos Montefiore Health System Jyoti Malhotra Dr. Ravi Salgia Stephen V Liu, MD Charu Aggarwal, MD, MPH, FASCO Ana I. Velázquez Mañana, MD, MSc, FASCO Narjust Florez, MD, FASCO Roy Herbst Solange Peters Vivek Subbiah, MD Edward S. Kim, MD, MBA, FACP, FASCO bet9 优德体育 足球 速8体育 彩金 江山美景图 彩娱乐 AB视讯 ECOG-ACRIN Cancer Research Group Strong work Matthew Lee

Sumanta K. Pal, MD, FASCO Matthew Lee Balazs Halmos Montefiore Health System Jyoti Malhotra Dr. Ravi Salgia Stephen V Liu, MD Charu Aggarwal, MD, MPH, FASCO Ana I. Velázquez Mañana, MD, MSc, FASCO Narjust Florez, MD, FASCO Roy Herbst Solange Peters Vivek Subbiah, MD Edward S. Kim, MD, MBA, FACP, FASCO bet9 优德体育 足球 速8体育 彩金 江山美景图 彩娱乐 AB视讯 ECOG-ACRIN Cancer Research Group We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing! oncodaily.com/opinion/sumant…

What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a new standard of care 1st-line ! We look forward to seeing the final OS data... #EGFR #lungcancer

News From Industry/ FLAURA2 Update Source AstraZeneca buff.ly/IxqmQjH Long-term follow-up from the Phase III FLAURA2 trial confirms that combining osimertinib with platinum-based chemotherapy and pemetrexed significantly improves overall survival in patients with

What’s next in the evolving landscape of EGFR and ALK targeting in NSCLC? 🫁 Prof Tom John from Australia will explore where we are – and what’s ahead for personalized strategies that drive outcomes. ✅ Register now for the ILCS on 26ᵗʰ September and join the conversation ⬇️

🔥BREAKING🆙 Positive OS‼️ ✅FLAURA2: Osimertinib + Chemo vs Osimertinib 🎯"Statistically significant and clinically meaningful improvement in the key secondary endpoint of OS" 🗣️AstraZeneca OncoAlert LARVOL #EGFR EGFR Resisters astrazeneca.com/media-centre/p…

Polling Q1. Emerging treatment options in SCLC ‼️ What is your current preferred 2L therapy for relapsed SCLC? #BTGLung2025 Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO OncLive.com Triparna Sen (Sen-Lab) Dr. Ravi Salgia

‼️Polling Q2. Emerging treatment options in SCLC What do you see as the most promising strategy to improve OS in SCLC? #BTGLung2025 Jacob sands Triparna Sen (Sen-Lab) Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO Ana I. Velázquez Mañana, MD, MSc, FASCO OncLive.com

Polling Q3. 1L EGFRm NSCLC‼️ When selecting for a 1L treatment option for a patient w/ EGFR+ mNSCLC, which single factor matters most? #BTGLung2025 Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO OncLive.com

Polling Q4. EGFRm NSCLC Beyond 1L‼️ Should EGFR inhibition be continued beyond progression? #BTGLung2025 Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO Balazs Halmos Xiuning Le MD PhD OncLive.com

Polling Q5. Early Stage NSCLC‼️ After recent updates, is chemo-IO ready for routine clinical use to convert borderline resectable NSCLC into resectable disease? #BTGLung2025 OncLive.com Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO Balazs Halmos Tejas Patil

Polling Q6. Early stage NSCLC‼️ If a patient with early-stage NSCLC achieves a pCR after neoadjuvant chemoimmunotherapy, is adjuvant immunotherapy still necessary? #BTGLung25 Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO OncLive.com Dr. Ravi Salgia

Polling Q8. AGA NSCLC‼️ Given the recent approval of Teliso-V, in your practice, are you routinely testing for c-MET overexpression? If so, when? #BTGLung2025 OncLive.com Christine Garcia, MD, MPH Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO

What defines platinum ineligibility (sPI) in NSCLC? Post Hoc Validation of Ph III IPSOS trial JTO & JTO CRR: - sPI: PS3, age>80yrs, PS2+ or age≥70+ comorbidities - 405pts (89%) sPI+ - these pts had ⬆️OS, ⬇️TRAEs with atezo Solange Peters OncoAlert #LCSM jto.org/article/S1556-…